Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study, to be published May 28 in the Journal of Experimental Medicine (JEM), shows that genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of NEPC tumors in mice, and lays the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans.

Researchers with the University of Cincinnati and Johns Hopkins Medicine developed a potential treatment for brain cancer that uses nanofibers embedded with a combination of drugs that work in concert to target tumors.

Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute, part of the National Institutes of Health, to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults (AYAs).

Living cells cool much slower than our current understanding of heat conduction can explain, according to new research from the University of Tokyo. Researchers used two techniques — high-speed temperature mapping and artificial heating — to observe how heat dissipated from living cells and similar-sized artificial, fluid-filled sacs (liposomes). While heat dispersed quickly from the artificial liposomes as expected, cells cooled significantly more slowly due to other biomolecules within the cell. Understanding the process behind slower heat dissipation within cells could affect how we treat conditions linked to changes in body temperature, such as epilepsy, inflammation and cancer.

Researchers at the Faculty of Information Technology at the University of Jyväskylä have used artificial intelligence to speed up the analysis of colorectal cancer samples and predict the functioning of the cells’ DNA repair mechanism. The AI model's analysis can help shorten diagnosis times, reduce costs, and improve the analysis's accuracy. The research was conducted in collaboration with the Central Finland Welfare Region and is co-funded by the European Union.

CHICAGO, MAY 27, 2026 ― In honor of their outstanding contributions to oncology, Sharon Giordano, M.D., chair of Breast Medical Oncology, and Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention, from The University of Texas MD Anderson Cancer Center will receive Special Awards at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.